Skip to content
OpenCapital
Get started

UroGen Pharma URGN Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$912M+0.6%
Pfizer logo
PfizerPFE
——
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
——
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
——

Other financials

Income statement

See full
Revenue$51.0M+152%
Gross profit$11.6M—
Operating income-$22.8M—
Net income-$23.6M+46.2%
EPS (diluted)-$1.17—

Balance sheet

See full
Cash & equivalents$110.0M+5.7%
Total debt$197.1M+56.0%
Total equity-$124.3M-167%
Total assets$253.7M+2.5%

Cash flow

See full
Operating cash flow-$45.3M-7.8%
CapEx$54.0K+22.7%
Free cash flow-$45.4M-7.8%

Valuation

See full
Market cap$1.73B+71.7%
Enterprise value$1.81B+80.9%
P/S12.3×+1.3×

Profitability

See full
Gross margin89.7%—
Operating margin-329.7%—
Net margin-94.8%-25.6pp
FCF margin-118.2%+1.3pp

Returns & leverage

See full
Return on equity-211.6%—
Debt / equity4.8×—
Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is UroGen Pharma's available for sale securities debt securities current?
UroGen Pharma (URGN) reported available for sale securities debt securities current of $30.31M in Q1 2026.
How has UroGen Pharma's available for sale securities debt securities current changed year-over-year?
UroGen Pharma's available for sale securities debt securities current decreased by 67.0% year-over-year, from $91.86M to $30.31M.
What is the long-term trend for UroGen Pharma's available for sale securities debt securities current?
Over 5 years (2020 to 2025), UroGen Pharma's available for sale securities debt securities current has grown at a -27.7% compound annual growth rate (CAGR), from $49.15M to $9.71M.